Fate Therapeutics 1 article

The scientific profile of Fate Therapeutics combines iPSC-derived immune cell therapies with off-the-shelf natural killer cell therapy, distinguishing the company from noncellular therapeutic developers. Its platform also involves iPSC-derived CAR NK cells and iPSC-derived T-cell therapeutics, with allogeneic cellular immunotherapy defining an important aspect of cell sourcing, genetic engineering, immune compatibility or ex vivo processing. Specific cell types, genetic modifications and therapeutic products remain distinct tags; the cellular strategy of Fate Therapeutics also includes hematologic malignancy cell therapy.

Clinical Trials & Evidence

September 19, 2026, 12:29 PM · 5 mins read

CAR-T clinical trial pipeline accelerates as over 180 companies advance next generation therapies

A surge of more than 180 companies is driving over 200 CAR-T therapies through the clinical pipeline, with new strategies aiming to overcome resistance and expand beyond cancer.